35 results about "Spermatogeny" patented technology

This invention provides a biomarker for spermatogenesis disorders and its application, wherein the biomarker is the MNDA molecule. This application characterizes the functional abnormalities or spermatogenesis disorders of Sertoli cells by detecting the expression level of MNDA molecules on cells in testicular tissue sections, and can therefore be used for the clinical diagnosis of non-obstructive azoospermia.

The invention discloses application of exosome-like nanoparticles derived from fructus lycii to preparation of a medicine for preventing or treating oligospermia and / or asthenospermia. Sterile, stable and high-purity fructus lycii exosome-like nanoparticles (LBELNs) are obtained by adopting a differential centrifugation-suction filtration-ultra-high-speed centrifugation method, the physiological efficacy of the LBELNs is researched, and it is found that the LBELNs can significantly improve the oligoasthenospermia disease activity index of male mice induced by cyclophosphamide (CTX); the sperm quantity is obviously increased, the sperm malformation is improved, the sperm motility is improved, and the sex hormone level is recovered. The LBELNs can effectively relieve spermatogenic dysfunction of testicular tissues, the sperm differentiation and formation process is obviously improved, the total number of sperms is increased, and the treatment effect is more obvious along with increase of the dosage of the LBELNs. The invention has potential in preparation of drugs for preventing or treating oligoasthenospermia, and provides a new strategy and treatment method for treating oligoasthenospermia.

The invention provides oleanolic acid, and a preparation method of the oleanolic acid comprises the following steps: S1, dissolving 5g of arginic acid in 500ml of dichloromethane, adding 7g of pyridinium dichlorochromate, stirring at room temperature for 18 hours, and detecting the reaction degree by thin-layer chromatography; s2, after the reaction is completed and vacuum concentration is carried out, a sample is mixed with 200-300-mesh silica gel, the mixture is volatilized to be dry and then placed on a silica gel column, column chromatography separation is carried out, petroleum ether / ethyl acetate is selected as a mobile phase, 2.87 g of oleanolic acid is obtained, the molecular formula is C30H46O3, and the yield is 57.6%. The oleanolic acid provided by the invention can be used for preparing medicines for treating oligospermia and medicines for improving dyszoospermia. The oleanolic acid provided by the invention is a natural product or an artificially synthesized product, is low in toxicity and small in side effect, and has good effects of improving dyszoospermia and promoting fertility.

This invention discloses a Fam205a1 Methods for constructing and applying gene knockout mouse models. The construction method utilizes CRISPR / Cas9 gene editing technology, targeting mice. Fam205a1 Gene-designed specific sgRNAs for knockout Fam205a1 The regions of exons 1 through 4 of the gene are obtained. Fam205a1 Gene knockout mice. Male mice in this model exhibit infertility, specifically characterized by impaired spermatogenesis, reduced sperm motility, abnormal sperm morphology (particularly head and acrosome defects), and spermatogenic cell apoptosis. However, the weight and appearance of their testes and epididymis show no significant difference from the wild type. The mouse model constructed in this invention has stable genetic traits and a well-defined phenotype, making it an ideal animal model for studying the mechanisms of idiopathic male infertility, screening drugs for treating male infertility, or developing male contraceptives.

The invention relates to the technical field of biological medicines, and discloses an application of a plant extract composition in preparation of a medicine for improving DNA damage of testicular spermatogenic cells, and the plant extract contains a herba epimedii extract and a rhizoma polygonati extract. The invention provides new application of the composition containing the herba epimedii extract and the rhizoma polygonati extract in preparation of the medicine for improving DNA damage of the testicular spermatogenic cells, the composition can remarkably improve the DNA damage of the testicular spermatogenic cells of mice caused by cyclophosphamide, recover the multiplication capacity of the mice, inhibit apoptosis of the mice and relieve spermatogenic function damage caused by cyclophosphamide, and the composition can be used for preparing the medicine for improving the DNA damage of the testicular spermatogenic cells of the mice. And the combined administration shows a synergistic effect instead of a simple additive effect, and the drug effect is obviously superior to that of any one of the epimedium extract and the rhizoma polygonati extract which are independently administered.

The invention belongs to the field of basic medical research, and particularly relates to a testicular toxicity animal model establishing method which comprises the following steps: performing intragastric administration on male rats with a preparation containing podophyllotoxin according to the dosage of 15 mg / kg per day; the medicine is continuously administrated for 4 days; according to the method, the rat can be induced to generate testicular toxicity phenotypes, and the phenotypes at least include that the number of sperms is remarkably reduced, the activity of the sperms is reduced, the testosterone level of serum is abnormally increased, and spermatogenic tubules in testicular tissue are irregular in shape and spermatogenic epithelium is thinned.

The application belongs to the technical field of biology, and discloses a method for activating an ASXL2-PRC2 axis, wherein adenovirus is injected into the seminiferous tubule of an organism through an outgoing pipe to activate the expression of endogenous EZH2 and spermatocyte-specific ASXL2 in the organism. The method can be used for reducing impaired sperm motility, increasing sperm penetration and tubulin polymerization, inhibiting abnormal spermatogenesis, down-regulating the transcription level of a TZ marker, increasing the enrichment of SUZ12, EED and H3K27me3 in CEP162 and CEP290 promoters under hypoxic conditions, and slowing down hypoxia-induced abnormal spermatogenesis and spermatocyte activation of the ASXL2-PRC2 axis in the germ cell line of the organism.

The invention relates to a compound microbial agent and application thereof, belongs to the technical field of microorganisms, and particularly discloses application of mixed fermented milk in a product for improving male functions. According to the application, the new application of the mixed fermented milk of the rhamnosus lactobacillus B6 and the streptococcus thermophilus XJ53 (CGMCC No.17323) in the aspect of improving male functions is disclosed for the first time, and the new application is specifically characterized by improving male fertility desire, reproductive capacity, seminiferous tubule dysfunction and spermatogenesis, testis oxidative stress activity, testis testosterone synthesis and sperm quality; the strain has a potential value of producing a gain substance for improving the male function by fermenting skimmed milk, and also prompts that the fermented milk has a potential application prospect for enhancing the male function.

The invention provides a pyrrolidone tricyclic compound and a preparation method thereof, and application of the pyrrolidone tricyclic compound in preparation of drugs for treating neurodegenerative diseases, especially antidepressant drugs. The structural formula of the pyrrolidone tricyclic compound is as shown in general formulas A and 13. Experimental studies on in-vitro PC12 cell injury protection activity, in-vivo mouse anti-depression activity, hERG potassium channel inhibition and mouse head shaking show that the compound disclosed by the invention can be used for preparing neurodegenerative diseases, especially quickly-acting anti-depression drugs, and has the remarkable advantage of improving the spermatogenesis function.

The invention belongs to the technical field of microorganisms, and particularly discloses application of lactobacillus rhamnosus fermented milk in a product for improving male functions. According to the application, the new application of the lactobacillus rhamnosus B6 (CGMCC No.13310) fermented milk in the aspect of improving male functions is disclosed for the first time, and the new application is specifically characterized by improving male fertility desire, reproductive capacity, seminiferous tubule dysfunction and spermatogenesis, testis oxidative stress activity, testis testosterone synthesis and sperm quality; the strain has a potential value of producing a gain substance for improving the male function by fermenting skimmed milk, and also prompts that the fermented milk has a potential application prospect for enhancing the male function.

The invention relates to the technical field of micro-fluidic organ chips, and discloses a micro-fluidic testis organ chip and a culture method, the micro-fluidic testis organ chip comprises a PDMS fluid control layer and a PDMS cell culture layer from top to bottom; the at least three culture units are arranged on the PDMS cell culture layer in the axial direction, each culture unit internally comprises three functional areas, the three functional areas are used for testicular sertoli cell culture, spermatogenic cell culture and basement membrane simulation respectively, and the three functional areas are communicated with one another to form a fluid path; the regulation and control part is arranged on the PDMS fluid control layer, and the regulation and control part is used for regulating and controlling fluid paths which are communicated with one another among the three functional areas; the inoculation and collection part is arranged on the PDMS fluid control layer and is used for carrying out cell inoculation and collection in the three functional areas. The in-vivo testis spermatogenesis microenvironment is highly simulated, the limitation of a traditional 2D cell experiment and an animal experiment can be effectively made up, and a new method and platform are provided for analyzing a spermatogenesis disorder mechanism and screening targeted repair drugs.

The invention belongs to the technical field of biological medicine, and particularly relates to application of 1, 3-propane diamine or pharmaceutically acceptable salt thereof in preparation of a medicine for preventing or treating male dyszoospermia. In a specific embodiment, the invention relates to application of 1, 3-propane diamine or pharmaceutically acceptable salt thereof in preparation of a medicine for preventing or treating male diabetic dyszoospermia. In experiments, the inventor finds that 1, 3-propane diamine can obviously improve the sperm concentration of diabetic mice and improve the expression quantity of testis spermatogenesis related proteins. According to the application, 1, 3-propane diamine is applied to diabetic dyszoospermia for the first time, an ideal treatment effect is achieved, a new treatment choice is provided for clinical application of 1, 3-propane diamine to treatment of diabetic dyszoospermia, and the application has extremely high application value and social benefits.

The application belongs to the technical field of reproductive health, and particularly relates to a new application of a testicular metabolite 2-n-propylthiazolidine-4-carboxylic acid (PTCA), and the 2-n-propylthiazolidine-4-carboxylic acid is used for preparing a drug for treating testicular spermatogenic disorder induced by AFB1. The PTCA can promote the secretion of testosterone of testicular interstitial cells, activate the PI3K / AKT / NRF2 antioxidant signaling pathway in testicular tissue, relieve testicular injury induced by AFB1, and reduce the ROS level in testicular tissue. The application discloses, for the first time, the important role of the PTCA as a new testicular metabolic marker and protective agent in the male reproductive system, provides a new insight into the reproductive toxicity mechanism of AFB1, and lays an experimental foundation for the application of metabolites to the intervention strategy of male spermatogenic disorder.

The application belongs to the technical field of biological medicine, and particularly relates to application of a reagent for inhibiting PPAR alpha expression in preparation of a medicine for treating male infertility diseases, wherein a PPAR alpha inhibitor (GW6471) or an active oxygen scavenger (NAC) is given to male mice exposed to cadmium water, it is found that the number of sperm in a Cd+GW6471 group is higher than that in a Cd+NAC group, the serum testosterone level in the Cd+GW6471 group is also higher than that in the Cd+NAC group, and the results of testicular tissue pathological staining also show that GW6471 can more significantly restore the decrease in the number of mature spermatogenic tubules caused by Cd, GW6471 restores the decrease in the number of SYCP3 positive spermatocytes caused by Cd, so that the sperm production efficiency is restored, and therefore the application of the reagent for inhibiting PPAR alpha expression in preparation of the medicine for treating male infertility diseases is proposed.

The invention relates to the technical field of medical detection, in particular to an antibody combination for detecting spermatogenic cells, a kit and application of the antibody combination. The antibody combination comprises an antibody of a zinc finger transcription factor 4, an antibody of a conjugation complex protein 3 and an antibody of zona pellucida binding protein. Specific recognition and semi-quantitative analysis of spermatogenic cells of all levels in samples are realized through standardized pretreatment, full-automatic immunohistochemical staining and digital image analysis for different types of samples; the method breaks through the technical bottlenecks that the traditional HE staining or Wright-Giemsa staining method is strong in subjectivity, difficult to distinguish cells with similar forms and greatly influenced by cell states and staining effects, and provides an efficient detection means for accurate pathological typing, spermatogenic function evaluation and dynamic curative effect monitoring of male infertility.

The invention discloses an RNA (Ribonucleic Acid) molecule, a nano-liposome and application of the RNA molecule to preparation of a product for treating testis injury and / or testis aging. The nucleotide sequence of the RNA molecule is as shown in SEQ ID NO. 1. The RNA molecule and the nano-liposome loaded with the RNA molecule provided by the invention show an excellent anti-inflammatory function and a remarkable targeting property in vivo, and most of the RNA molecule and the nano-liposome loaded with the RNA molecule can be taken by testis macrophages, so that the treatment effect is effectively improved, the repair and regeneration of testis tissues are promoted, the spermatogenic ability of testis is remarkably improved, the normal reproductive endocrine environment is recovered, and the curative effect is good. The testosterone level is improved. The invention provides a brand new technical strategy for treating testis injury, improving testis aging and improving male fertility, and is expected to play an important role in future clinical application.

The invention relates to the technical field of biological medicines, and provides an application of promoting spermatogenesis by regulating lysine succinylation modification. Nicotinamide can change the lysine succinylation modification level of protein in mouse testis and effectively promote spermatogenesis. The invention provides a new treatment scheme for clinical treatment of sperm production disorder.

The invention belongs to the technical field of biological medicines, and particularly relates to application of fumaric acid in preparation of a product for preventing, improving or treating male dyszoospermia. In a specific embodiment, the invention relates to application of fumaric acid in preparation of a product for preventing, improving or treating senile male dyszoospermia. In experiments, the inventor finds that fumaric acid can obviously improve the sperm concentration of old mice, improve the number of spermatogenic cells and improve the serum testosterone level of the old mice. The fumaric acid is used for treating the male reproductive dysfunction of the elderly for the first time, an ideal treatment effect is achieved, a new choice is provided for clinically treating the male reproductive dysfunction of the elderly, and the fumaric acid has extremely high application value and social benefits.

The invention discloses application of sodium 4-phenylbutyrate in a product for improving dyszoospermia of obese males, and belongs to the technical field of biological medicines. High-fat feed is adopted to construct a rat obesity model, the protection effect of 4-PBA on the reproductive function of obese rats is studied, and experimental results show that after the 4-PBA intervenes the obese rats, the testosterone content can be obviously increased, the estradiol level can be reduced, the sperm motility can be improved, the sperm malformation rate can be reduced, the spermatogenic dysfunction can be obviously relieved, and the anti-obesity effect on testis tissue morphology, testis tissue morphology, testis tissue morphology, testis tissue morphology and testis tissue morphology can be improved. The functions of supporting cell mitochondria, endoplasmic reticulum and MAM structures are obviously improved, and a new treatment strategy and a new drug target are provided for intervening and controlling obesity induced testis dyszoospermia and improving fertility of obese males.

The invention provides a model for studying testis diminution, relates to the technical field of biomedicine, and has the technical key points that Papd7 is a key gene for testis growth and development of male mice through specific experiments. Specifically, after Papd7 is knocked out in a mouse body, compared with a control mouse, the weight of a Papd7 deficient mouse is normally developed, testis can only be developed to half of the size, and correspondingly, the sperm density and activity are only half of those of the control group; and the sperm morphology of the defective mouse is abnormal. In mechanism, testis section staining finds that the testis of the knockout mouse become smaller due to the loss of sperm cells in seminiferous tubules; disorder of various hormones is also one of important reasons. Experimental results show that the Papd7 is a key gene for growth and development of the testis of the mouse, the growth defect of the testis of the mouse can be caused by damaging the function of the Papd7 in the mouse through a CRISPR-Cas9 technology, and the Papd7 is a useful model for researching the testis reduction.

The invention belongs to the field of medicines for treating male infertility diseases, and discloses application of 12-ketolithocholic acid (12-keto-LCA) in the aspect of improving sperm quality decline, namely application of 12-keto-LCA in preparation of medicines for improving sperm quality decline. The invention provides a new application of 12-keto-LCA, reveals for the first time that 12-keto-LCA can support the spermatogenesis process, especially can improve the reproductive function of obese males, realizes the effects of improving testosterone secretion, repairing the spermatogenic function, improving the sperm quality and embryonic developmental ability and the like, and improves the condition that the sperm quality of mammals is reduced. The 12-keto-LCA can effectively relieve dyszoospermia of males, especially relieve damage of obesity to the reproductive function of males, and a new way is provided for developing drugs for improving the reproductive function of obese males.

The invention discloses cistanche uniform oligosaccharide, a preparation method thereof and application of the cistanche uniform oligosaccharide in prevention and treatment of diabetic spermatogenic dysfunction, and belongs to the technical field of biology. The cistanche uniform oligosaccharide contains glucose, arabinose, galactose, mannose and glucosamine, and the corresponding molar ratio of the glucose to the arabinose to the galactose to the mannose to the glucosamine is 75.08: 11.05: 7.92: 3.70: 2.25. The molecular weight of the cistanche uniform oligosaccharide is 1390Da; the structure of the cistanche uniform oligosaccharide is mainly alpha-(1, 4) (1, 6)-glucan. An in-vitro biological activity test shows that the uniform oligosaccharide of cistanche deserticola can reduce oxidative stress damage of high glucose to TM4 cells, inhibit cell apoptosis and improve blood testis barrier damage through a Keap1-Nrf2 / HO-1 pathway, and has the potential of preventing and treating diabetic spermatogenic dysfunction.

The invention belongs to the technical field of reproductive health, and particularly relates to a new application of testis metabolite 2-propyl thiazolidine-4-carboxylic acid (2-n-propyylthiazolidine-4-carboxylic acid, PTCA), an application of the 2-propyl thiazolidine-4-carboxylic acid in preparation of a medicine for treating testis dyszoospermia induced by AFB1, the PTCA can promote testis interstitial cell testosterone secretion, and the medicine for treating testis dyszoospermia induced by AFB1 can be used for treating testis dyszoospermia induced by AFB1, so that the testis dyszoospermia induced by AFB1 can be used for treating testis dyszoospermia induced by AFB1. The PI3K / AKT / NRF2 antioxidant signal channel in the testis tissue is activated, the testis injury induced by AFB1 is relieved, and the ROS level in the testis tissue is reduced; according to the application, the important effect of PTCA as a novel testis metabolism marker and protective agent in the male reproductive system is disclosed for the first time, a new insight is provided for understanding the reproductive toxicity mechanism of AFB1, and an experimental foundation is laid for an intervention strategy of metabolite applied to male dyszoospermia.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a reagent for inhibiting PPARalpha expression in preparation of a medicine for treating male infertility diseases, a PPARalpha inhibitor (GW6471) or an active oxygen scavenger (NAC) is given to male mice exposed to cadmium water, it is found that the sperm number of a Cd + GW6471 group is higher than that of a Cd + NAC group, the serum testosterone level of the Cd + GW6471 group is also higher than that of the Cd + NAC group, and the PPARalpha inhibitor (GW6471) or the active oxygen scavenger (NAC) is applied to the male mice exposed to cadmium water. The result of pathological staining of the testis tissue also shows that the GW6471 can more obviously recover the reduction of the number of mature seminiferous tubules caused by Cd, and the GW6471 recovers the phenomenon of reduction of the number of SYCP3 positive spermatocytes caused by Cd, so that the spermatogenesis efficiency is recovered, and the spermatogenesis effect is improved. Therefore, the invention provides the application of the reagent for inhibiting the expression of the PPARalpha in preparing the medicine for treating the male infertility disease.

The invention discloses a biological clock protein Cry-melatonin combined medicine as well as a preparation method and application thereof, and belongs to the field of biological medicines. The core components of the combined drug comprise a recombinant expression vector containing a biological clock protein Cry gene and melatonin; the preparation process comprises preparation of the recombinant expression vector containing the biological clock protein Cry gene, preparation forming and combined packaging. According to the combined medicine disclosed by the invention, through the synergistic effect that the Cry recombinant expression vector regulates MT1 / 2 receptor expression and melatonin inhibits a TLR4 / NF-kappa B inflammation pathway, mRNA and protein expression of inflammatory factors can be remarkably reduced, testis-epididymis pathological injuries can be repaired, spermatogenesis related gene expression can be up-regulated, so that the sperm malformation rate is reduced, the sperm quality is recovered, and the curative effect is good. The invention has the advantages of high safety and no drug resistance risk, can be applied to the treatment of testis-epididymitis of male mammals, provides potential technical reference for the treatment of human male reproductive system inflammation, and has important significance in the fields of endangered animal protection, animal husbandry development and reproductive medicine.

The application discloses application of a natural product composition in preparation of medicines for preventing or treating azoospermia. The natural product composition is composed of astragalin and curcumin. The natural product composition composed of astragalin and curcumin can inhibit spermatogenic cell apoptosis by synergistically regulating Nrf2 / HO-1 / HIF-1a, and improve rat azoospermia. Compared with western medicines, the natural product composition has a wider treatment window and smaller toxic side effect, and has application prospects in the medicines for preventing or treating azoospermia.

The invention belongs to the field of male infertility disease treatment, and discloses an application of Eileum Valurensis in improvement of sperm quality decline, the strain is named as Ileibacterium valensLiu-M1, and is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC M 20252545. The strain provided by the invention is separated and identified from a fresh excrement sample of an inulin-intervened high-fat diet mouse by adopting a bacterial separation and identification method. In-vivo research finds that the live ileobium varrensii can improve the reproductive function of obese male mice, and has the effects of improving testosterone secretion, repairing spermatogenic functions, improving sperm quality and embryonic developmental ability and the like. Experimental results show that the ileobibacter wallenii can significantly improve sperm quality decline related to obesity, and prompt that the ileobibacter wallenii has the potential of becoming a microbial candidate drug for treating the reproductive function of obese males.

The invention discloses an application of L-phenylalanyl-L-lysine in improving a spermatogenic function. The L-phenylalanyl-L-lysine is proposed for the first time to be capable of remarkably increasing sperm concentration, improving sperm malformation, improving sperm motility and effectively improving the spermatogenic function. Meanwhile, L-phenylalanyl-L-lysine is used for treating oligoasthenozoospermia, can promote thickening of spermatogenic tubule spermatogenic cell layers, increase spermatogenic cell areas, improve sperm differentiation and formation processes, relieve spermatogenic dysfunction of testicular tissues and increase the total number of sperms, is remarkable in treatment effect and high in safety, and has excellent clinical transformation prospects.

The application of F5-peptide and / or P-gp inhibitor in the preparation of drugs crossing blood-testis barrier and oral targeted nanoparticles and drugs, for the first time, F5-peptide is used to destroy the physical barrier of BTB, and Tariquidar is used to inhibit the biochemical barrier of BTB, so that the BTB is instantaneously opened and closed, the basal ES protein and the tight junction protein are no longer closely connected with the BTB near the basement membrane, and the P-gp transporter cannot pump the exogenous drug Adjudin out of the BTB, so that the Adjudin is successfully transported to the spermatogenic epithelium, and the FAF5T-LAN oral targeted nano-preparation carrying active Adjudin molecules is constructed, and is expected to become a high-compliance male contraceptive, and has important social significance and economic value.

The application belongs to the field of male infertility disease treatment, and discloses application of a valens enterobacter in improving sperm quality decline. Ileibacterium valens Liu-M1, which is preserved in China Center for Type Culture Collection (CCTCC) and has a preservation number of CCTCC M 20252545. The strain of the application is obtained by using a bacterial separation and identification method to separate and identify a fresh fecal sample of a high-fat diet mouse intervened by inulin. In vivo research finds that the live valens enterobacter can improve the reproductive function of obese male mice, has the effects of improving testosterone secretion, repairing spermatogenesis function, improving sperm quality and embryo development capacity and the like. Experimental results of the application show that the valens enterobacter can significantly improve obesity-related sperm quality decline, which indicates that the valens enterobacter has the potential to become a microbial candidate drug for treating obesity male reproductive function.